{"id":56569,"date":"2024-02-27T16:59:23","date_gmt":"2024-02-27T16:59:23","guid":{"rendered":"https:\/\/medsname.com\/desowen\/"},"modified":"2026-05-01T10:49:13","modified_gmt":"2026-05-01T10:49:13","slug":"desowen","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/desowen\/","title":{"rendered":"Desowen"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Desowen?<\/h3>\n

Desowen<\/strong> obsahuje desonide 0.05%<\/strong> as a topical lotion from Galderma — a mild \/ low-potency topical corticosteroid (UK Class I \/ US Class VII-VI)<\/strong>. Because it is mild, desonide is one of the safest topical steroids for use on the face, eyelids (with dermatology guidance), neck, intertriginous folds, and in paediatric patients (including infants 3 months and older)<\/strong>. Pou\u017e\u00edv\u00e1 se k atopic dermatitis (eczema), seborrhoeic dermatitis, contact dermatitis, intertrigo, discoid lupus<\/strong>, and other steroid-responsive inflammatory skin conditions where a mild steroid is sufficient or where a potent steroid would cause atrophy. Apply a thin film twice daily<\/strong> for up to 4 weeks on body sites, 2 weeks on the face, 1 week on eyelids or intertriginous zones. Desonide’s favourable safety margin makes it a first-choice steroid in paediatric dermatology, but it should still be used under guidance for the shortest necessary course.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

What Is Desowen?<\/h2>\n

Desowen is a topical desonide 0.05%<\/strong> lotion from Galderma supplied in a 30 mL lotion. Desonide is a synthetic non-fluorinated glucocorticoid classified as a low-potency topical corticosteroid<\/strong> (UK Class I \/ US Class VI-VII, sometimes called “mild” on European potency scales). It is the molecule of choice when facial, paediatric, or intertriginous application demands a safety profile that moderate and potent steroids cannot offer.<\/p>\n

Mezin\u00e1rodn\u011b zna\u010dkov\u00e1n jako Desowen, DesoRx, Verdeso (foam), Tridesilon<\/strong> (US); Desowen is the Galderma version available through MedsBase with worldwide shipping.<\/p>\n

Topical Steroid Potency Ladder — Where Desonide Sits<\/h2>\n\n\n\n\n\n\n\n\n
Britsk\u00e1 t\u0159\u00edda<\/th>\nAmerick\u00e1 t\u0159\u00edda<\/th>\nP\u0159\u00edklady<\/th>\n<\/tr>\n<\/thead>\n
I (m\u00edrn\u00fd)<\/td>\nVII-VI<\/td>\nHydrokortizon 0,5-1 %, desonid 0,05 % (Desowen)<\/strong><\/td>\n<\/tr>\n
II (st\u0159edn\u011b siln\u00fd)<\/td>\nV<\/td>\nKlobetason butyr\u00e1t, betamethason valer\u00e1t 0,025%<\/td>\n<\/tr>\n
III (siln\u00fd)<\/td>\nIII\u2013II<\/td>\nBetamethasonvaler\u00e1t 0,1 % (Betnovate<\/strong>), mometason 0,1 % (Elocon<\/a>, Momin<\/a>), flutikason (Flutivate<\/a>)<\/td>\n<\/tr>\n
IV (velmi siln\u00fd)<\/td>\nI<\/td>\nKlobetasolpropion\u00e1t 0,05 % (Tenovate<\/a>), halobetasolpropion\u00e1t 0,05 % (Halox<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Desonide sits in the mildest tier alongside hydrocortisone 0.5-1%. The key advantage over hydrocortisone is that desonide is non-halogenated<\/strong> — meaning it has one of the lowest skin-atrophy and telangiectasia risks of any topical steroid, making it appropriate for thin-skin areas (face, eyelids, paediatric) where potent steroids are contraindicated.<\/p>\n

How Desowen Works<\/h2>\n

Desonide binds intracellular glucocorticoid receptors in keratinocytes and infiltrating inflammatory cells. The activated receptor complex enters the nucleus and downregulates pro-inflammatory cytokine transcription (IL-1, IL-2, IL-6, TNF-α), suppresses phospholipase A2<\/sub> (reducing prostaglandin\/leukotriene synthesis), and triggers apoptosis of activated T-lymphocytes — resolving the itch-redness-inflammation cycle of eczema and related dermatoses.<\/p>\n

Onset: itch and redness begin to improve in 24-48 hours; full effect within 1-2 weeks.<\/p>\n

Schv\u00e1len\u00e9 a v\u011bdecky podlo\u017een\u00e9 indikace<\/h2>\n